The Cambridge Life Sciences and Technology team advised CMR Surgical on their recent $165 million fundraising.
CMR is a Cambridge (UK)-based company with worldwide operation which develops, manufactures and distributes Versius®, the only small and modular surgical robot powered by a digitally native ecosystem. Built for precision, dexterity and versatility, Versius® has been specifically designed to meet the needs of patients, surgeons and the surgical team. By providing minimal access surgery with enhanced accuracy and control for complex procedures, Versius® helps surgeons and surgical teams to deliver high-quality surgical care.
The financing comes just as CMR Surgical have announced that their Versius® Surgical Robotic System has now been used to perform over 15,000 surgical cases globally in more than 20 countries and across a wide range of surgical specialties including general, urological, gynaecological and thoracic. This new injection of fundraising will be used to support continued product innovation and commercial growth in existing and key new markets around the world.
The funding round was led by all of its major existing investors, including Ally Bridge Group, Cambridge Innovation Capital, Escala Capital, LGT and its affiliate impact investing platform Lightrock, RPMI Railpen, SoftBank Vision Fund 2, Tencent and Watrium.
The Goodwin team included David Mardle, Elizabeth Rhodes, Duy Le, Laura Kelly and Andrew Crouch.
For more details on the fundraising, please see here.